https://www.merck.com/news/moderna-and-merck-announce-mrna-4157-v940-an-investigational-individualized-neoantigen-therapy-in-combination-with-keytruda-pembrolizumab-demonstrated-superior-recurrence-free-survival-in/
Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy,...
Apr 17, 2026 - mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients with...
mrna 4157 v940